31 January 2025 in Infection and Immunity
The incidence of infections attributed to antimicrobial-resistant (AMR) pathogens has increased exponentially over the recent decades reaching 1.27 million deaths worldwide in 2019. Without intervention, these infections are predicted to cause up to 10 million deaths a year and incur costs of up to 100 trillion US dollars globally by 2050. The emergence of AMR bacteria such as the ESKAPEE pathogens, and in particular Pseudomonas aeruginosa and species from the genus Burkholderia , underscores an urgent need for new therapeutic strategies. Monoclonal antibody (mAb) therapy offers a promising alternative to treat and prevent bacterial infections. In this study, we used peptides from highly conserved areas of the bacterial flagellin to generate monoclonal antibodies capable of broad binding to flagellated Gram-negative bacteria. We generated a broadly reactive IgG2bĸ mAb (WVDC-2109) that recognizes P. aeruginosa, Burkholderia sp., and other Gram-negative pathogens of interest. Characterization of the therapeutic potential of this antibody was determined using P. aeruginosa as model. In vitro characterization of WVDC-2109 demonstrated complement-mediated bactericidal activity and enhanced opsonophagocytosis of P. aeruginosa . Prophylactic administration of WVDC-2109 markedly improved survival and outcome in a lethal sepsis model and a sub-lethal murine pneumonia model of P. aeruginosa infection, reducing bacterial burden and inflammation. These findings suggest that WVDC-2109 and similar FliC-targeting antibodies could be valuable in preventing or treating diseases caused by P. aeruginosa as well as other life-threatening diseases of concern. IMPORTANCE: Antimicrobial resistance (AMR) costs hundreds of thousands of lives and billions of dollars annually. To protect the population against these infections, it is imperative to develop new medical countermeasures targeting AMR pathogens like P. aeruginosa and Burkholderia sp. The administration of broadly reactive monoclonal antibodies can represent an alternative to treat and prevent infections caused by multi-drug-resistant bacteria. Unlike vaccines, antibodies can provide protection regardless of the immune status of the infected host. In this study, we generated an antibody capable of recognizing flagellin from P. aeruginosa and B. pseudomallei along with other Gram-negative pathogens of concern. Our findings demonstrate that the administration of the monoclonal antibody WVDC-2109 enhances survival rates and outcomes in different murine models of P. aeruginosa infection. These results carry significant implications in the field given that there are no available vaccines for P. aeruginosa .
5 September 2022 in Urolithiasis
The use of double J ureteral stents can lead to several adverse effects, as urinary infection. Bacteria tend to colonize the stent surface, leading to the formation of bacterial biofilms. The presence of urease-producing bacteria increase the urine pH leading to the incrustation and blockage of the stent. On the other hand, these large crystalline masses function as niduses, allowing the attachment of even more bacteria and decreasing its exposure to antibiotics. The aim of this in vitro study was to assess the effect of phytate on the attachment of bacteria to the catheter surface under conditions that favor crystallization. Catheter sections were incubated in a synthetic urine medium (pH 6.5) in the presence or absence of Pseudomonas aeruginosa and phytate. Amount of calcium deposits was measured using an Arsenazo III colorimetric method and the number of attached bacteria to the stent was determined. Differences were assessed using an ANOVA with a Bonferroni post hoc test. The formation of calcium phosphate deposits (brushite and hydroxyapatite) and oxalate crystals (COM), as were as the amount of bacteria decreased when phytate was present. Thus, phytate successfully decreased bacterial adhesion by inhibiting the formation of crystalline deposits.
29 July 2025 in Scientific Reports
MGM. Trinidad García-Barceló
M. Trinidad García-Barceló
ADAntonio Doménech-Sánchez
+1
Pseudomonas aeruginosa is a primary driver of morbidity and mortality in cystic fibrosis (CF) patients. Throughout the course of infection, P. aeruginosa undergoes significant evolution and adaptation to the dynamic environment of the CF respiratory tract, leading to the emergence of diverse phenotypes. Among the variants that arise during this process are mutations in the regulatory gene lasR. While clinical significance of LasR deficiency is well recognized, current evidence does not fully elucidate the metabolic changes associated with the absence of this master regulator. To address this, we conducted untargeted metabolic profiling of cell supernatants (exometabolomes) to compare twenty-four P. aeruginosa strains, collected over 3–8 years from ten CF patients classified either as LasR functional (LasR+) or LasR non-functional (LasR−). We found a highly significant relationship between the LasR phenotype and the global exometabolic profile of the clinical strains. Furthermore, our analysis identified several metabolites whose production appears to be linked to LasR expression. These findings were validated using a loss of function/gain of function approach. This connection between lasR genetic expression, the chronic adaptation of P.aeruginosa to the CF lung environment and the generation of traceable metabolic markers highlights a potential avenue for diagnosing and monitoring respiratory infections caused by this pathogen.
18 June 2026 in Scientific Reports
MGM. Trinidad García-Barceló
M. Trinidad García-Barceló
AGAlexandre González-Alsina
Alexandre González-Alsina
ADAntonio Doménech-Sánchez
+1
Pseudomonas aeruginosa is an opportunistic respiratory pathogen frequently affecting hospitalized patients and individuals with chronic lung diseases such as cystic fibrosis (CF), bronchiectasis, and chronic obstructive pulmonary disease (COPD). Current diagnostic methods for airway infection are often invasive or lack sensitivity, highlighting the need for non-invasive approaches. Volatile organic compounds (VOCs) released by microbes represent promising candidates for non-invasive detection of respiratory pathogens. In this study we characterized the volatilome of clinical P. aeruginosa isolates and identified candidate VOC markers associated with bacterial metabolism. An untargeted volatilomics workflow based on gas chromatography–mass spectrometry (GC–MS) was applied to profile the in vitro VOCs produced by 48 clinical P. aeruginosa isolates associated with acute and chronic respiratory infections. We identified three previously unrecognized VOCs consistently produced by all isolates, suggesting conserved metabolic features of P. aeruginosa. Comparative analysis revealed marked metabolic differences between infection phenotypes: chronic isolates produced higher levels of aliphatic volatiles, whereas acute isolates were enriched in aromatic compounds, particularly acetophenone. Longitudinally sampled clonally related isolates from CF patients exhibited distinct and evolving volatilomic signatures, indicating metabolic adaptation over the course of chronic infection. Because LasR dysfunction is common during chronic airway colonization, we further assessed its impact on VOC production. LasR-functional isolates produced elevated levels of sulfur-containing VOCs and specific ketones, while LasR-deficient isolates displayed increased alcohol production. Overall, our findings show that isolates from chronic infections are associated with a shift from aromatic to aliphatic VOCs compared to acute isolates, and highlight volatilomics as a powerful tool for probing metabolic adaptation in P. aeruginosa and for identifying candidate VOC markers associated with infection-related phenotypes.